Please ensure Javascript is enabled for purposes of website accessibility

Medtronic Under Federal Investigation For Ventilator Shortage

By The Daily Upside – Oct 2, 2020 at 7:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has denied all allegations of wrongdoing

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter.  It's completely free and we guarantee you'll learn something new every day.

In the early days of the pandemic, a shortage of ventilators was one of the most pressing challenges for the healthcare system.  

Now, U.S. officials are investigating whether industry consolidation in the ventilator market played a role in causing the shortage. 

According to the WSJ, the Justice Department has issued a civil subpoena to Medtronic, the $140 billion med-tech giant, as part of an ongoing investigation.


Photo Credit: Getty Images.

Ventilator Consolidation
The focus of the probe is a series of acquisitions stemming back to 2012. The story begins when device maker Covidien PLC purchased Newport Medical Instruments, a small ventilator manufacturer for $108 million.

Newport had secured a contract to supply low-cost ventilators to the federal government, but the project stalled after Covidien bought Newport.  The two sides eventually agreed to terminate the contract before any ventilators were delivered.

A few years later, Medtronic swallowed Covidien (and with it, Newport) in a $50 billion deal. The purchase helped secure Medtronic's place as a pillar in the ventilator market.

Both deals were cleared by antitrust regulators.

The Accusation
In April, members of the House antitrust subcommittee sent a letter to the FTC Chairman questioning whether the Newport deal was to blame for the shortage of ventilators:

  • An excerpt from the letter read: "Covidien's purchase of a potentially market-disrupting competitor...has all the hallmarks of a killer acquisition, where an incumbent firm acquires and then shuts down a key rival."

Medtronic, which inherited the problem in a nesting doll scenario, has denied the accusations.  A company spokesman said the industry remains competitive, "with at least 10 major players in which the top five account for approximately 50% market share."

The Takeaway: The ventilator shortage, knock on wood, is behind us.  Medtronic's problems might just be beginning.

The Motley Fool has a disclosure policy.  The Motley Fool has partnered with The Daily Upside to bring you news and highlights from the financial world. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.